Brokerages expect Bruker Co. (NASDAQ:BRKR) to report $0.24 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Bruker’s earnings, with estimates ranging from $0.24 to $0.25. Bruker also reported earnings per share of $0.24 during the same quarter last year. The firm is scheduled to announce its next earnings report on Thursday, May 2nd.
According to Zacks, analysts expect that Bruker will report full year earnings of $1.57 per share for the current year, with EPS estimates ranging from $1.55 to $1.59. For the next year, analysts expect that the firm will post earnings of $1.74 per share, with EPS estimates ranging from $1.70 to $1.77. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Bruker.
Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, February 11th. The medical research company reported $0.54 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.54. The business had revenue of $553.60 million for the quarter, compared to analysts’ expectations of $544.53 million. Bruker had a return on equity of 26.36% and a net margin of 9.48%.
BRKR has been the topic of a number of analyst reports. Zacks Investment Research cut Bruker from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 7th. BTIG Research reaffirmed a “buy” rating and issued a $44.00 price objective (up from $42.00) on shares of Bruker in a research report on Tuesday, February 12th. Needham & Company LLC initiated coverage on Bruker in a research report on Wednesday, January 2nd. They issued a “strong-buy” rating and a $39.00 price objective on the stock. BidaskClub raised Bruker from a “hold” rating to a “buy” rating in a research report on Friday, January 11th. Finally, Deutsche Bank raised Bruker from a “hold” rating to a “buy” rating and upped their price objective for the company from $40.00 to $50.00 in a research report on Friday, April 12th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $38.14.
Shares of BRKR traded down $0.41 during mid-day trading on Friday, reaching $38.51. The company had a trading volume of 4,850 shares, compared to its average volume of 700,331. The company has a quick ratio of 1.33, a current ratio of 2.18 and a debt-to-equity ratio of 0.36. Bruker has a 52 week low of $26.10 and a 52 week high of $40.25. The stock has a market cap of $6.09 billion, a P/E ratio of 27.49, a P/E/G ratio of 2.18 and a beta of 1.47.
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 22nd. Stockholders of record on Tuesday, March 5th were paid a $0.04 dividend. The ex-dividend date of this dividend was Monday, March 4th. This represents a $0.16 annualized dividend and a dividend yield of 0.42%. Bruker’s dividend payout ratio (DPR) is 11.43%.
Large investors have recently bought and sold shares of the company. Vanguard Group Inc boosted its holdings in Bruker by 1.0% in the 3rd quarter. Vanguard Group Inc now owns 10,210,783 shares of the medical research company’s stock worth $341,550,000 after buying an additional 101,913 shares during the period. Vanguard Group Inc. boosted its holdings in Bruker by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 10,210,783 shares of the medical research company’s stock worth $341,550,000 after buying an additional 101,913 shares during the period. BlackRock Inc. boosted its holdings in Bruker by 2.6% in the 4th quarter. BlackRock Inc. now owns 5,465,722 shares of the medical research company’s stock worth $162,713,000 after buying an additional 139,004 shares during the period. AQR Capital Management LLC boosted its holdings in Bruker by 28.4% in the 3rd quarter. AQR Capital Management LLC now owns 2,243,794 shares of the medical research company’s stock worth $75,055,000 after buying an additional 496,259 shares during the period. Finally, Norges Bank bought a new position in Bruker in the 4th quarter worth $49,346,000. Hedge funds and other institutional investors own 68.89% of the company’s stock.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Recommended Story: Why does a company issue an IPO?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.